Tartalom

Prémium Noble Kava
Fedezze fel a tanúsított minőséget és tisztaságot hivatalos partnerünknél.
A Kava-mode.com oldalraRöviden & tömören
Kava can interact with medicines and other central nervous system depressants. Laboratory findings show several possible CYP inhibitions, but small human studies do not confirm one uniform pattern across all enzymes. Alcohol and sedatives in particular should not be self-combined; regular medication warrants individual review.
- ●Alkohol – Additive drowsiness and impaired coordination are possible; concurrent use is not recommended
- ●Benzodiazepinekkel – Possible additive CNS depression; combine only after professional review
- ●Antipszichotikumok – Sedation and pharmacokinetic interactions are possible; direct clinical data are limited
- ●Antikoagulánsok – Controlled interaction data are lacking; the narrow therapeutic window requires medical review
A citokróm P450 rendszer
A citokróm P450 rendszer (CYP450) egy enzimek családja a májban, amely a legtöbb gyógyszer lebontásáért felelős. Ha egy anyag gátolja ezeket az enzimeket, más anyagok lebontása lassabbá válik – ezáltal fokozódhat a hatásuk és mellékhatásaik.
Miért fontos ez?
Many medicines are metabolised by CYP enzymes. An in-vitro finding does not automatically mean clinically relevant inhibition in humans. Preparation, dose, duration and the medicine's therapeutic window determine practical relevance.
Mely enzimek gátlódnak?
Mathews et al. (2002) tested kava extract and individual kavalactones in human liver microsomes and found inhibition of several CYP enzymes. These are in-vitro findings, not clinical inhibition ratings in humans:
| Enzim | Gátlási erősség | Fontos szubsztrátok (példák) |
|---|---|---|
| CYP1A2 | In-vitro finding | Koffein, Theophyllin, Clozapin, Olanzapin |
| CYP2C9 | In-vitro finding | Warfarin, Phenytoin, NSAID-ok (Ibuprofen) |
| CYP2C19 | In-vitro finding | Omeprazol, Diazepam, Clopidogrel |
| CYP2D6 | In-vitro finding | Kodein, Tramadol, sok antidepresszáns |
| CYP3A4 | In-vitro finding | Benzodiazepinek, sztatinok, sok antibiotikum |
Klinikai jelentőség
Russmann et al. (2005) reported reduced CYP1A2 activity in chronic users of traditional aqueous kava. Gurley et al. (2005; 12 healthy volunteers, 28 days, 138 mg kavalactones/day), by contrast, found reduced CYP2E1 but no significant change in CYP1A2, CYP2D6 or CYP3A4/5. The human findings are small and preparation- and consumption-dependent, so they cannot predict every medicine interaction.
Magas kockázatú kombinációk
The following combinations should be avoided or medically reviewed in advance. Reasons differ: some involve additive CNS effects or case reports, while others have only mechanistic signals and no controlled combination trials.
⚠ Alkohol
Risiko: AVOID
Concurrent use of kava and alcohol is not recommended:
- 1.Additive CNS effects: Drowsiness, slower reactions and impaired coordination may increase.
- 2.Liver risk not quantified: A combined liver risk has not been quantified reliably; the combination is avoided because of this uncertainty.
- 3.Unpredictable intensity: Product, amount, drinking pattern and individual sensitivity make effects difficult to predict.
Do not use kava and alcohol together. The main practical reason is possible additive impairment of attention, reaction and coordination; the size of any additional liver risk is not reliably established.
⚠ Benzodiazepinek és altatók
Risiko: PROFESSIONAL REVIEW
Do not combine benzodiazepines or Z-drugs with kava without medical review:
- •Additive sedation: Drowsiness and psychomotor impairment may increase.
- •CNS depression: Clinically relevant potentiation is possible; controlled combination trials are lacking.
- •Interpret CYP findings: CYP3A4 inhibition was observed in vitro but not consistently confirmed in small human studies.
Esettanulmány: Almeida & Grimsley (1996) described a semicomatose state in a 54-year-old man after reported kava and alprazolam use. A single case report is a warning signal but does not establish mechanism or frequency.
⚠ Antipszichotikumok
Risiko: PROFESSIONAL REVIEW
Individual medical review is appropriate before kava use with antipsychotics:
- •Sedation: Additive drowsiness or psychomotor impairment is possible.
- •Case reports: Individual reports describe movement disorders; frequency and causality are unclear.
- •CYP findings: Laboratory inhibition does not reliably predict the level of a specific medicine.
⚠ Antikoagulánsok (vérhígítók)
Risiko: PROFESSIONAL REVIEW
Warfarin, phenprocoumon and other anticoagulants require professional review because of their narrow therapeutic window:
- •Mechanistic signal: CYP2C9 inhibition was observed in vitro; a clinical kava-warfarin interaction has not been established in controlled studies.
- •Monitor INR: Changes in co-used products should be coordinated with the treating clinician.
- •Bleeding risk: The baseline risk of anticoagulation makes self-testing inappropriate.
Use kava with anticoagulation only after individual medical review.
Mérsékelt kockázatú kombinációk
A következő kombinációk óvatosságot igényelnek, és csak orvosi konzultáció után alkalmazhatók. Dózismódosítás szükséges lehet.
Antidepresszánsok
Risiko: PROFESSIONAL REVIEW
- • Pharmacokinetic interactions may occur depending on the product but are not clinically established as a class
- • Serotonin syndrome from kava is not established as a typical clinical effect
- • Additive drowsiness or dizziness are possible
- • Direct clinical combination data are limited
- • Review co-medication individually rather than inferring from in-vitro CYP data
- • MAO-B effects of individual kavalactones have been studied preclinically
- • Pawa et al. (2026) found MAO-A inhibition by flavokawain A in an in-vitro enzyme assay; humans and combination with MAO inhibitors were not studied
- • Do not self-combine with MAO inhibitors because medicine interactions can be serious
- • Obtain medical review before use
Antikonvulzív szerek (antiepileptikumok)
Risiko: PROFESSIONAL REVIEW
Phenytoin, Carbamazepin, Valproat és más antikonvulzív szerek:
- •Pharmacokinetics: Altered levels are possible but cannot be predicted reliably for individual combinations.
- •CNS effects: Additive drowsiness or coordination problems are possible.
- •Seizure control: Changes in co-used products belong under professional supervision.
Epilepszia esetén a Kava csak orvosi felügyelet mellett használható.
Parkinson-gyógyszerek
Risiko: PROFESSIONAL REVIEW
Levodopa és dopamin agonisták:
- •Mechanism unclear: Blanket clinical dopamine antagonism by kava has not been established.
- •Case reports: Individual reports describe worsening Parkinson symptoms; medical review is therefore needed.
With Parkinson's disease or related medication, use kava only after medical review.
Hepatotoxikus gyógyszerek
Risiko: MÉRSÉKELT
Ismert hepatotoxikus potenciállal rendelkező gyógyszerek:
- •Paracetamol/Acetaminophen: Különösen magas dózisok esetén problémás.
- •Sztatinok: Atorvastatin, Simvastatin stb. (CYP3A4 szubsztrátok)
- •Methotrexat: Immunmoduláló szer májtoxicitással.
- •Isoniazid: TBC-gyógyszer.
Additional liver risk is plausible but not quantified for every combination. Potentially hepatotoxic medication requires individual medical review.
Kölcsönhatások áttekintő táblázata
| Anyagcsoport | Példák | Kockázat | Mechanizmus |
|---|---|---|---|
| Alkohol | Ethanol | AVOID | Possible additive sedation and impaired coordination; liver risk not quantified |
| Benzodiazepinek | Diazepam, Lorazepam, Alprazolam | PROFESSIONAL REVIEW | Possible additive CNS depression; one case report, no controlled combination trials |
| Antipszichotikumok | Haloperidol, Olanzapin, Clozapin | PROFESSIONAL REVIEW | Sedation or interactions possible; direct clinical data limited |
| Antikoagulánsok | Warfarin, Phenprocoumon | PROFESSIONAL REVIEW | No controlled kava interaction established; narrow therapeutic window |
| SSRI-k | Fluoxetin, Sertralin, Paroxetin | PROFESSIONAL REVIEW | Possible sedation or pharmacokinetics; no established kava serotonin syndrome |
| Antikonvulzív szerek | Phenytoin, Carbamazepin | PROFESSIONAL REVIEW | Possible additive CNS effects and unpredictable pharmacokinetics |
| Parkinson-gyógyszerek | Levodopa, dopamin agonisták | PROFESSIONAL REVIEW | Case reports of symptom worsening; no blanket dopamine antagonism established |
| Sztatinok | Atorvastatin, Simvastatin | PROFESSIONAL REVIEW | Direct clinical interaction data are lacking; review liver and medication context |
| Opioidok | Kodein, Tramadol, Morfin | AVOID / REVIEW | Possible additive CNS depression |
| Koffein | Kávé, energiaitalok | CAUTION | Human CYP1A2 findings are small and inconsistent |
Gyakorlati ajánlások
Ellenőrző lista Kava fogyasztása előtt
- 1.Gyógyszerlista ellenőrzése
Minden aktuális gyógyszert ellenőrizzen a kölcsönhatások szempontjából.
- 2.Orvos konzultálása
Rendszeres gyógyszerszedés esetén orvosi tanácsot kérjen Kava fogyasztása előtt.
- 3.Alkohol kerülése
Do not use kava and alcohol together. The main practical reason is possible additive impairment of attention, reaction and coordination; the size of any additional liver risk is not reliably established.
- 4.Alacsony dózisban kezdeni
Do not experiment with a self-selected lower kava dose while taking medicines; obtain professional review of the combination.
- 5.Tünetek figyelése
Figyeljen az szokatlan fáradtságra, szédülésre vagy más tünetekre.
Tovább a Biztonság fejezetben
Hozzájárulásokkal
Ez a wiki egy kurált erőforrás, amely lektorált tanulmányok és szakértő kutatók kutatásait szintetizálja. Nem az fent felsorolt kutatók írták, hanem a közzétett munkáikon alapul.
Tudományos források
Az ezen az oldalon található információk a következő tudományos tanulmányokon és publikációkon alapulnak:
Cytochrome P450 2E1 (CYP2E1) Is the Principal Enzyme Responsible for Urethane Metabolism
Hoffler U., El-Masri H.A., Ghanayem B.I. (2003) – Journal of Pharmacology and Experimental Therapeutics
Tanulmány megtekintéseKava: From Ethnology to Pharmacology
Yadhu N. Singh (Editor) (2004) – CRC Press
Tanulmány megtekintése

